- TRADE NAME: Praluent (Regeneron)
- INDICATIONS: Adjunct to diet and statin therapy in hypercholesterolemia or clinical atherosclerotic cardiovascular disease where additional lowering of low density lipoprotein cholesterol is required
- CLASS: Monoclonal antibody, Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor
- HALF-LIFE: 17–20 days
- FDA APPROVAL DATE: 07/24/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No data available but likely to cross the placenta in second and third trimester
- See adverse reactions attributed to class:
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
